Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — Februar 2013

Planlagt Fastgjort Låst Flyttet Genmab
189 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • D Offline
    D Offline
    deleted-user
    wrote on sidst redigeret af
    #93

    60 dage efter submission. Ikke lang tid

    1 Reply Last reply
    0
    • S Offline
      S Offline
      Sukkeralf
      wrote on sidst redigeret af
      #94

      Nej det er ikke lang tid, men omvendt der er jo heller ikke så mange data de skal kigge igennem ! Tak for link gentogen

      1 Reply Last reply
      0
      • S Offline
        S Offline
        Sukkeralf
        wrote on sidst redigeret af
        #95

        Spændende om den store blok i 99,30 bliver liggende

        1 Reply Last reply
        0
        • MadsSkjernM Offline
          MadsSkjernM Offline
          MadsSkjern
          wrote on sidst redigeret af
          #96

          Daratumumab passer som fod i hose til det program!

          1 Reply Last reply
          0
          • S Offline
            S Offline
            Sukkeralf
            wrote on sidst redigeret af
            #97

            Hvis man kigger på clinical trials, så er "primary completion date" juli 2013 og "study completion date" december 2013

            1 Reply Last reply
            0
            • S Offline
              S Offline
              Sukkeralf
              wrote on sidst redigeret af
              #98

              Hvis man sammenholder det med hvad Paul Richardson sagde på post ASH seminaret - nemlig at mulighed for hurtig godkendelse var "very real" såfremt data var gode - og det viste man i løbet af et halvt års tid, så passer det med "primary completion date"

              1 Reply Last reply
              0
              • S Offline
                S Offline
                Sukkeralf
                wrote on sidst redigeret af
                #99

                Så måske er det efter dette, at man vil søge om breakthrough disignation, hvis altså det reelt er noget de overvejer !

                1 Reply Last reply
                0
                • MadsSkjernM Offline
                  MadsSkjernM Offline
                  MadsSkjern
                  wrote on sidst redigeret af
                  #100

                  Hvis ikke de søger, så gør jeg 🐵

                  1 Reply Last reply
                  0
                  • D Offline
                    D Offline
                    deleted-user
                    wrote on sidst redigeret af
                    #101

                    hahaha mads. Genialt

                    1 Reply Last reply
                    0
                    • D Offline
                      D Offline
                      deleted-user
                      wrote on sidst redigeret af
                      #102

                      der er godt smæk på idag 172k nu @gen.co

                      1 Reply Last reply
                      0
                      • R Offline
                        R Offline
                        Repsac
                        wrote on sidst redigeret af
                        #103

                        Det kan da ikke bare være DDB nye kursmål der giver mængde og stigning i dag.

                        1 Reply Last reply
                        0
                        • D Offline
                          D Offline
                          deleted-user
                          wrote on sidst redigeret af
                          #104

                          der bliver handlet igennem nu

                          1 Reply Last reply
                          0
                          • D Offline
                            D Offline
                            deleted-user
                            wrote on sidst redigeret af
                            #105

                            316K

                            1 Reply Last reply
                            0
                            • SolsenS Offline
                              SolsenS Offline
                              Solsen
                              wrote on sidst redigeret af
                              #106

                              http://www.bloomberg.com/news/2013-02-15/genmab-rises-as-danske-sees-fda-breakthrough-copenhagen-mover.html?cmpid=yhoo Måske allerede posted

                              1 Reply Last reply
                              0
                              • D Offline
                                D Offline
                                deleted-user
                                wrote on sidst redigeret af
                                #107

                                det er merill lynch, credit suisse på den ene side og ens og ddb på den anden side. Jeg tror det må være ATP der losser ud

                                1 Reply Last reply
                                0
                                • G Offline
                                  G Offline
                                  gentogen
                                  wrote on sidst redigeret af
                                  #108

                                  Vedr. Solsens link. Så kan Ofa måske profitere af Ibrutinib. In combination with ofatumumab (Arzerra) on patients with chronic lymphocytic leukemia / small lymphocytic leukemia / prolymphocytic leukemia1 (CLL/SLL/ PLL1) and Richter transformation, results demonstrate that the combination was well-tolerated and highly active in patients with heavily pretreated relapsed/refractory CLL/SLL. The drug is described to have a rapid onset of response, low relapse rate, and favorable safety profile.http

                                  1 Reply Last reply
                                  0
                                  • G Offline
                                    G Offline
                                    gentogen
                                    wrote on sidst redigeret af
                                    #109

                                    http://www.prohostbiotech.com/_blog/News_and_Comments/post/PHARMACYCLICS_IBRUTINIB,_THE_NEXT_RITUXAN_AND_MORE_/

                                    1 Reply Last reply
                                    0
                                    • G Offline
                                      G Offline
                                      gentogen
                                      wrote on sidst redigeret af
                                      #110

                                      eller det modsatte http://clinicaltrials.gov/ct2/show/NCT01578707?term=ofatumumab&phase=2&rank=11

                                      1 Reply Last reply
                                      0
                                      • G Offline
                                        G Offline
                                        gentogen
                                        wrote on sidst redigeret af
                                        #111

                                        In this ongoing trial patients with relapsed/refractory CLL/SLL who have received two or more prior therapies are treated with ibrutinib (420 mg) daily until disease progression, followed by concomitant ofatumumab with continued ibrutinib until progression.

                                        For the CLL/SLL/PLL patients the overall response rate, as measured by IWCLL criteria and progression-free survival is 100%, with a median follow-up of 9.8 months

                                        1 Reply Last reply
                                        0
                                        • D Offline
                                          D Offline
                                          deleted-user
                                          wrote on sidst redigeret af
                                          #112

                                          Så de laver head to head med ofa i den indikation den er godkendt i. Det er svært at se fordelen i for Genmab.

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger